Altered RNA splicing initiates the viral mimicry response from inverted SINEs following type I PRMT inhibition in Triple-Negative Breast Cancer
Cheryl Arrowsmith,Qin Wu,David Nie,Wail alawi,Jennifer Cruickshank,Jillian Haight,YiShuai Ji,Felipe Ciamponi,Yudao Shen,Jing Liu,Jocelyn Chen,Shili Duan,Sajid Marhon,Parinaz Mehdipour,Magdalena Szewczyk,Nergiz Artun,Wenjun Chen,Lan Xin Zhang,Genevieve Deblois,Panagiotis Prinos,Katlin Maussirer,Dalia Barsyte-Lovejoy,Jian Jin,Daniel De Carvalho,Benjamin Haibe-Kains,David Cescon,Mathieu Lupien
DOI: https://doi.org/10.21203/rs.3.rs-649284/v1
2021-01-01
Abstract:Abstract Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype with the worst prognosis and few effective therapies. Here, we undertook a screen of epigenetic chemical probes to systematically uncover the epigenetic regulators critical for TNBC growth. We identified MS023, an inhibitor of type I protein arginine methyltransferases (PRMTs), as having anti-tumor growth activity in TNBC in vitro and in vivo. Pathway analysis of TNBC cell lines indicates that the activation of interferon responses pre- and post-MS023 treatment is a functional biomarker and determinant of response; and these observations extend to a panel of patient-derived organoids. Inhibition of type I PRMT triggers an interferon response through the antiviral defense pathway with the induction of double-stranded RNA (dsRNA). The observed dsRNA accumulation is derived, at least in part, from inverted-repeat Alus (IR-Alus), many of which are expressed from retained introns induced by MS023, which inhibits arginine methylation of RNA-binding proteins and alters mRNA splicing machinery. Together, our results represent a shift in understanding the anti-tumor mechanism of type I PRMT inhibitors and provide a novel rationale and biomarker approach for the clinical development of type I PRMT inhibitors.